Enavate Sciences GP, LLC

Est. AUM

$351.51B

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	SIONNA THERAPEUTICS INC	COM	$99.34B	2478030	28.26%	SOLE
2	IMMUNOME INC	COM	$79.03B	3613799	22.48%	SOLE
3	ZENAS BIOPHARMA INC	COM	$76.62B	3919159	21.80%	SOLE
4	COMPASS THERAPEUTICS INC	COM	$41.20B	7788150	11.72%	SOLE
5	BRIDGEBIO ONCOLOGY THERAPEUT	COM NEW	$23.51B	2626946	6.69%	SOLE
6	UPSTREAM BIO INC	COM	$22.14B	2459703	6.30%	SOLE
7	CAMP4 THERAPEUTICS CORP	COM	$9.66B	2190920	2.75%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.